Covidien Public Limited Company. (COV), Ireland-based healthcare products supplier, on Monday said its pharmaceutical subsidiary, Mallinckrodt, entered into a definitive agreement to acquire all the outstanding capital stock of CNS Therapeutics, Inc, a private pharma company focusing on products involved in the treatment of neurological disorders and intractable chronic pain, for $100 million. The company noted the acquisition shall not be accretive in terms of sales or earnings for the fiscal 2013.
CNS Therapeutics, which holds one marketed product, has a pipeline of pain and spasticity products in development. The deal is believed to close in the fourth quarter of this year, said Covidien in a statement.
The stock is currently trading at $59.17, down $0.60 or 1.00 percent on the NYSE.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.